Emergence of the novel H7N9
A new deadly influenza A H7N9 strain of avian influenza virus, first identified in China in March 2013 with human and avian cases, has been observed in various eastern and inland Chinese provinces [1, 2] . There have been a total of 132 confirmed cases with 43 deaths with people over 60 appearing to be more susceptible to the H7N9-associated severe respiratory disease [3] [4] [5] [6] . Patients infected by H7N9 have exhibited viral pneumonia, acute kidney failure, acute respiratory distress syndrome, diffuse intravascular coagulation and septic shock. Although the H7N9 subtype can be highly virulent in humans, it exhibits low pathogenicity in avian hosts perhaps due in part to the absence of a multi-basic amino acid sequence at the hemagglutinin cleavage site[1, 7, 8] . Infected chickens, however, can shed virus very efficiently via the oropharynx, and we and others have observed limited shedding by the cloacal route despite no clinical signs of infection (unpublished data; Liu et al. and [9] ). This unusual low pathogenicity of the avian H7N9 viruses makes an H7N9 infection in avian species hard to detect and to monitor. Experts remain fearful of the potential for this virus to mutate into a form easily transmissible between humans, although to date, there has been no clear confirmation of humanto-human transmission [4] .
Genetic analysis shows that the novel H7N9 virus is a triple reassortant virus carrying genes from H7N3, H9N2 and H11N9 or H2N9 avian influenza A viruses. It is assumed that the novel H7N9 subtype virus was generated by a single or double independent reassortment event in ducks or chickens in China [10] . Most of the H7N9 viruses carry certain mammalian adaptation signatures (i.e. PB2-627K, HA-226L), which have been proved critical in mammalian adaption and transmission based on previous studies [11] and especially the 226L in the H7 HA protein based on our unpublished data (Liu et al. submitted) . Virulence and transmissibility of this novel H7N9 influenza virus have been characterized in different mammalian animal models, including mice, ferrets, macaques and pigs [7, 9, [12] [13] [14] . In ferrets, the H7N9 virus showed transmission by direct contact among ferrets and limited transmissibility by respiratory droplets [7, [12] [13] [14] .
Moreover, the novel H7N9 virus replicated efficiently in both upper and lower respiratory tracts of infected nonhuman primates (cynomolgus macaques). Emergent H7N9 viruses isolated from recent human cases have increased infectivity and lethality in mice when compared to avian H9N2 viruses and genetically related H7N9 viruses isolated from wild birds before 2013 [7, 12] .
Swine are an important intermediate host for influenza viruses [15] ; one of the concerns is that of H7N9 viruses may jump into pigs, they might replicate efficiently in this host, adapt to the mammalian receptor repertoire and reassort with endemic swine influenza viruses. Previous studies showed that pigs infected intranasally with H7N9 viruses did not transmit virus to contact pigs [14] , while pigs infected intratracheally with H7N9 can transmit to sentinel animals with low efficiency (Liu et al., submitted). These facts warrant increased surveillance for H7N9 influenza viruses in pigs.
Antivirals and Tamiflu

® resistance of the novel H7N9 virus
The novel H7N9 virus rapidly spread over a large geographic region in China after the first reported case in March 2013 with the live poultry markets thought to be the source of human infections, suggesting that H7N9 viruses might be silently prevalent in poultry in China [10] .
Continuing detection in poultry and sporadic human infections raises concerns on the emergence of a H7N9 virus, which can efficiently transmit between humans. Vaccination is a very efficient way to prevent influenza infection; however, no commercial vaccine specific for H7N9 is currently available. Moreover, humans lack any immunological memory against H7N9, which is another concern of its potential to result in a pandemic if easy human to human transmission is acquired.
Antiviral treatment is an important strategy in helping to control and prevent influenza infections. As recommended by the CDC in Atlanta, USA, antiviral treatment against influenza infections should be applied as early as possible, ideally within 48 hours after onset of illness.
Antiviral drugs are readily available to treat influenza infections including this novel H7N9
virus. For influenza infections, M2-ion channel blockers (e.g., amantadine and rimantadine) and neuraminidase inhibitors (e.g., oseltamivir, zanamivir, and peramivir) have been mainly used as antiviral drugs and those compounds are approved by the Food and Drug Administration (FDA) [16, 17] . However, the H7N9 is resistant to both amantadine and rimantadine because a S31N mutation exists in the M2 protein, which confers M2-ion channel blocker resistance [18] .
Therefore, the neuraminidase inhibitors are the only FDA approved compounds, which can be used for the treatment of the novel H7N9 infection and other M2-ion channel blocker resistant influenza viruses [19] .
Clinical studies show that oseltamivir treatment reduces the viral load in the respiratory tract of patients with H7N9 infection [5] . However, some patients with oseltamivir treatment failure had a poor clinical outcome. Further studies on the H7N9 viruses isolated from those patients showed that an R292K substitution occurred in the NA protein; this NA change is associated with resistance to all neuraminidase inhibitors including oseltamivir (Tamiflu ® ) [20] . Surprisingly, in humans treated with oseltamivir, the R292K substitution occurred as early as 2 days post treatment with the 292K genotype becoming the predominant virus population at 7 days post treatment. Neuraminidase inhibition assays using the resistant H7N9 virus showed 100-fold and 30-fold reduced susceptibility to the two FDA approved inhibitors, oseltamivir and zanamivir, respectively [5] . Subsequently, neuraminidase inhibitor resistance of H7N9 viruses in humans resulted in antiviral treatment failure and a poor clinical outcome. Further studies confirmed that H7N9 isolates with a dominant 292K genotype are resistant to zanamivir, peramivir, and oseltamivir, although this resistance can be masked by a mixed R/K genotype on position 292 of the NA protein in a viral quasispecies population [21] . Rapid emergence of antiviral drug resistant mutants after treatment with oseltamivir or zanamivir is raising concerns about the prevalence of such resistant H7N9 viruses in the humans and other mammalian populations. This emphasizes the importance of the development of new antiviral influenza drugs or the use of already developed FDA approved drugs for other infectious diseases, which might also work against influenza. Other influenza antivirals are under development, including thiazides that are anti-influenza molecules targeting the viral hemagglutinin at the post-translational level [22] ; Favipiravir (T-705), a novel viral RNA polymerase inhibitor [23] ; Aprotinin, a protease inhibiting the cleavage of the HA protein [24] . None of these compounds, however, have been approved for clinical treatment for influenza infection.
Alferon N inhibits replication of oseltamivir resistant and sensitive H7N9 viruses in vitro
Type I interferons (IFN) including IFN alpha and beta produced by host cells in response to the presence of viral pathogens, play a critical role in pathogen clearance during infection [25] .
Previous studies showed that the 2009 pandemic H1N1 and the highly pathogenic H5N1 viruses are highly sensitive to the antiviral actions of type I IFNs [26, 27] . Type I IFN upregulates the expression of several IFN-stimulated antiviral gene products, such as protein kinase R (PKR), 2',5'-oligoadenylate synthetase (OAS) and the Mx protein [28] . The activated PKR phosphorylates the eukaryotic initiation factor eIF2α, thereby inhibiting viral mRNA translation and viral replication [29] . OAS inhibits viral protein synthesis [28] ; and the Mx protein interacts with viral components to block generation of new virus particles [26, 30] .
Alferon N (IFN-α-n3) is a natural IFN alpha product derived from human leukocytes. In previous studies using SARS virus, Alferon N was the only IFN-based drug to be active against SARS virus at clinically achievable serum levels with the failure of other tested IFN-based clinical products [31] . Additionally Alferon N has a better safety profile than recombinant IFNs [32] . We Figure 1B ). Alferon N with a concentration of 10,000 IU/ml significantly reduced Anhui/1/H7N9 virus load at 36 hours post infection, and all three doses (100 IU/ml, 1000 IU/ml and 10,000 IU/ml) significantly inhibit replication of oseltamivir sensitive Anhui/1/H7N9 and oseltamivir resistant Shanghai/1/H7N9 at 48 hours post infection ( Figure 1B) . Our data demonstrates that Alferon N is effective against both oseltamivir sensitive and resistant H7N9 viruses and provides sufficient evidence to justify the costly in vivo studies (BSL3/BSL3Ag) required for regulatory approval.
Expert commentary and five-year view
The emergence of NA inhibitor resistant strains of the novel H7N9 virus in treated patients requires alternative antiviral compounds for human therapy, which will be critical in case of a potential pandemic. Our results show that both oseltamivir (Tamiflu 
